MUSC Hollings Cancer Center researchers have uncovered a new way to exploit a weakness in triple-negative breast cancer (TNBC), an aggressive form of breast cancer that often develops resistance to chemotherapy. The team discovered a previously unknown role for the protein LOX inside cancer cells, where it helps to support energy production, healthy mitochondria and other processes the cells rely on to survive.

When researchers blocked LOX, the cancer cells became vulnerable but adapted by relying more heavily on a backup survival pathway controlled by a protein called DHODH. The team, led by Hollings researcher Ozgur Sahin, Ph.D., turned that adaptation against the cancer with a “one-two punch”: first blocking LOX to weaken the cells, then blocking DHODH to cut off their escape route. The combination significantly blocked tumor growth across multiple patient-derived models without chemotherapy and showed potential advantages over pairing the LOX-blocking drug with standard chemotherapy.

The findings are still preclinical, but they point toward a potential strategy for treating chemotherapy-resistant TNBC while one day reducing reliance on chemotherapy and its serious side effects. The researchers also found evidence that LOX and DHODH could potentially serve as biomarkers to help identify patients most likely to benefit. The team is now developing a newer LOX-blocking drug and completing studies needed to move the approach toward testing in people.

Researchers at UC San Diego have been awarded a DARPA contract to redesign red blood cells to temporarily boost human performance.

Immunotherapy for gynecological tumors is in a period of rapid development, bringing new hope to patients but also facing some new problems. How to achieve better clinical translation and improve treatment strategies based on current experimental research requires our joint efforts.

Hepatocellular carcinoma (HCC) typically develops in chronically inflamed and cirrhotic livers, where malignant hepatocytes are continuously exposed to immune pressure. Although cytotoxic immunity is essential for tumor control, persistent immune activation may paradoxically enable cancer cells to acquire adaptive traits that support disease progression. How this chronic immune pressure contributes to the initiation of metastasis in HCC, however, remains poorly understood.